Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Cladribine+Venetoclax After Failure of Venetoclax+Hypomethylating Agent in Monocytic AML

NCT06232655 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT06232655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06232655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Cladribine+Venetoclax After Failure of Venetoclax+Hypomethylating Agent in Monocytic AML
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 8, 2024
Completion date
October 31, 2027
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia